Aleniglipron
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Aleniglipron
- Molecular weight
- 916.01
- Structure (SMILES)
- CCP(=O)(CC)c1ccc(-n2ccn(-c3c4c(nn3-c3cc(C)c(F)c(C)c3)CCN(C(=O)c3cc5cc(C6CCOCC6)ccc5n3[C@@]3(c5nc(=O)o[nH]5)C[C@@H]3C)[C@H]4C)c2=O)cc1NC
- aleniglipron
- Aleniglipron
- aleniglipron [INN]
- ALENIGLIPRON [USAN]
- aleniglipron inn
- aleniglipron usan
- gsbr 1001290
- gsbr 1290
- GSBR-1001290
- GSBR-1290
- gsbr1001290
- GSBR1001290
- gsbr1290
- GSBR1290
- CAS registry numbers
- 2685823-26-9
- ChEMBL ID
- CHEMBL6068040
- InChIKey
- CPOJUYUGONJVPZ-WIXASUBBSA-N
- PubChem compound IDs
- 164809721
- FDA ingredient codes (UNII)
- Z6XCL6R9SX
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- aleniglipron
- Type
- Synthetic organic
- Drug name stem
- -glipron
Mechanisms of action
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 10
- Affinity units
- pEC50
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- HP_0025502
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Hydrogen bond acceptors
- 13
- Hydrogen bond donors
- 2
- Polar surface area
- 167.21
- Calculated partition coefficient (ALogP)
- 7.71
- Calculated partition coefficient (XLogP)
- 6.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 11
- Heavy atoms
- 66
- Molecular formula
- C49H55FN9O6P
- Monoisotopic mass
- 915.39969567
- Natural product
- No
Related records
Trials (7)
- A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
- A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
- Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus